The effect of alpha-adrenergic blocking drugs on reducing the excitatory symptoms of ureteral stent placement

Phase 2

• Conditions: reteral canal stenosis.; Displacement of urinary stent; T83.122

• Registration Number: IRCT20201006048950N3
• Lead Sponsor: Arak University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

lack of Underlying disease, especially nephrogenic cardiovascular problems, allergies, other urological diseases, urinary retention, diabetes, malignancy in the urinary tract, chronic pelvic pain syndrome, lower urinary tract symptoms
No drug addiction
Age less than 81 years
Informed consent
One-sided G stent placement

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction of stent-dependent stimulus symptoms. Timepoint: Take drug:one dose daily for 4-6 weeks. Method of measurement: Questionnaires 1- Symptoms related to stent placement (USSQ) 2- International Prostate Symptoms Questionnaire (IPSS) 3- Quality of Life Questionnaire (QOL).